{"id":2013,"date":"2017-09-30T21:11:04","date_gmt":"2017-09-30T19:11:04","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=2013"},"modified":"2017-09-30T21:12:25","modified_gmt":"2017-09-30T19:12:25","slug":"la-fda-aprueba-una-nueva-formulacion-autoinyectable-de-benlysta","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=2013","title":{"rendered":"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta"},"content":{"rendered":"<div class=\"small-12 medium-12 large-12 row\" data-equalizer=\"\">\n<div class=\"small-9 medium-9 large-9 columns\" data-equalizer-watch=\"\">\n<p>GSK ha anunciado que la<\/p>\n<h2>FDA\u00a0ha a<b>probado una nueva formulaci\u00f3n subcut\u00e1nea de Benlysta (belimumab) para el tratamiento de pacientes adultos con lupus eritematoso sist\u00e9mico<\/b> (LES) activo, con anticuerpos positivos pese al tratamiento est\u00e1ndar.<\/h2>\n<p>El LES es la forma m\u00e1s com\u00fan del lupus, una enfermedad autoinmune cr\u00f3nica e incurable que produce autoanticuerpos que pueden atacar pr\u00e1cticamente a cualquier sistema del organismo. Esta aprobaci\u00f3n <b>marca la llegada de la primera opci\u00f3n de tratamiento mediante inyecci\u00f3n subcut\u00e1nea para los pacientes con esta enfermedad.<\/b><\/p>\n<blockquote><p><span style=\"color: #993366;\">Los pacientes, una vez formados por su m\u00e9dico, <b>podr\u00e1n autoadministrarse la medicaci\u00f3n una vez a la semana en forma de inyecci\u00f3n de 200 mg<\/b><\/span>.<\/p><\/blockquote>\n<p>Esta es la segunda formulaci\u00f3n de Benlysta que recibe la aprobaci\u00f3n para el tratamiento del LES. La formulaci\u00f3n intravenosa (i.v.) existente, que se aprob\u00f3 en 2011, se administra en dosis basadas en el peso de 10 mg\/kg mediante perfusi\u00f3n de una hora, en un entorno hospitalario o ambulatorio, cada cuatro semanas.<\/p>\n<p><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-2015 alignright\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg\" alt=\"GSK\" width=\"300\" height=\"164\" srcset=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg 300w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329.jpg 642w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p><em><span style=\"color: #000000;\">Vlad Hogenhuis, Senior Vice President, Head of Specialty Care de GSK<b>,<\/b>ha declarado que: <\/span><\/em><\/p>\n<blockquote><p><span style=\"color: #993366;\">\u201c&#8230; nos alegramos de esta decisi\u00f3n. El lupus afecta a las vidas de los pacientes de muchas maneras distintas y les causa s\u00edntomas diversos y, a menudo, impredecibles. Desde que se lanz\u00f3 Benlysta en su formato i.v., se ha tratado a miles de pacientes de todo el mundo con este f\u00e1rmaco. La aprobaci\u00f3n de una nueva formulaci\u00f3n inyectable brindar\u00e1 a partir de ahora una opci\u00f3n adicional para los pacientes, y les permitir\u00e1 autoadministrarse la medicaci\u00f3n en casa en vez de tener que acudir al hospital o a la consulta para recibir una perfusi\u00f3n\u201d.<\/span><\/p><\/blockquote>\n<p>En otros pa\u00edses hay solicitudes de aprobaci\u00f3n adicionales previstas o en proceso de revisi\u00f3n para la formulaci\u00f3n subcut\u00e1nea de Benlysta durante 2017.<\/p>\n<p>Noticia aparecida en <a href=\"http:\/\/www.elglobal.net\/industria-farmaceutica\/la-fda-aprueba-una-nueva-formulacion-autoinyectable-de-benlysta-JY1067694\">ElGlobal.net<\/a> el 28 de julio 2017<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>GSK ha anunciado que la FDA\u00a0ha aprobado una nueva formulaci\u00f3n subcut\u00e1nea de Benlysta (belimumab) para el tratamiento de pacientes adultos con lupus eritematoso sist\u00e9mico (LES) activo, con anticuerpos positivos pese al tratamiento est\u00e1ndar. El LES es la forma m\u00e1s com\u00fan del lupus, una enfermedad autoinmune cr\u00f3nica e incurable que produce autoanticuerpos que pueden atacar pr\u00e1cticamente [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[36,48,19,16],"class_list":["post-2013","post","type-post","status-publish","format-standard","hentry","category-lupus-internacional","tag-belibumab","tag-benlysta","tag-informacion","tag-tratamientos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=2013\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"GSK ha anunciado que la FDA\u00a0ha aprobado una nueva formulaci\u00f3n subcut\u00e1nea de Benlysta (belimumab) para el tratamiento de pacientes adultos con lupus eritematoso sist\u00e9mico (LES) activo, con anticuerpos positivos pese al tratamiento est\u00e1ndar. El LES es la forma m\u00e1s com\u00fan del lupus, una enfermedad autoinmune cr\u00f3nica e incurable que produce autoanticuerpos que pueden atacar pr\u00e1cticamente [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=2013\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2017-09-30T19:11:04+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2017-09-30T19:12:25+00:00\" \/>\r\n<meta property=\"og:image\" content=\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta\",\"datePublished\":\"2017-09-30T19:11:04+00:00\",\"dateModified\":\"2017-09-30T19:12:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#primaryimage\"},\"thumbnailUrl\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg\",\"keywords\":[\"Belibumab\",\"Benlysta\",\"Informaci\u00f3n\",\"Tratamientos\"],\"articleSection\":[\"Lupus Internacional\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2013#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013\",\"url\":\"https:\/\/lupusgalicia.org\/?p=2013\",\"name\":\"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#primaryimage\"},\"thumbnailUrl\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg\",\"datePublished\":\"2017-09-30T19:11:04+00:00\",\"dateModified\":\"2017-09-30T19:12:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2013\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#primaryimage\",\"url\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg\",\"contentUrl\":\"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2013#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=2013","og_locale":"es_ES","og_type":"article","og_title":"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta - Asociaci\u00f3n Galega de Lupus","og_description":"GSK ha anunciado que la FDA\u00a0ha aprobado una nueva formulaci\u00f3n subcut\u00e1nea de Benlysta (belimumab) para el tratamiento de pacientes adultos con lupus eritematoso sist\u00e9mico (LES) activo, con anticuerpos positivos pese al tratamiento est\u00e1ndar. El LES es la forma m\u00e1s com\u00fan del lupus, una enfermedad autoinmune cr\u00f3nica e incurable que produce autoanticuerpos que pueden atacar pr\u00e1cticamente [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=2013","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2017-09-30T19:11:04+00:00","article_modified_time":"2017-09-30T19:12:25+00:00","og_image":[{"url":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg","type":"","width":"","height":""}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=2013#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=2013"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta","datePublished":"2017-09-30T19:11:04+00:00","dateModified":"2017-09-30T19:12:25+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2013"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2013#primaryimage"},"thumbnailUrl":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg","keywords":["Belibumab","Benlysta","Informaci\u00f3n","Tratamientos"],"articleSection":["Lupus Internacional"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=2013#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=2013","url":"https:\/\/lupusgalicia.org\/?p=2013","name":"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2013#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2013#primaryimage"},"thumbnailUrl":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg","datePublished":"2017-09-30T19:11:04+00:00","dateModified":"2017-09-30T19:12:25+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=2013#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=2013"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=2013#primaryimage","url":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg","contentUrl":"http:\/\/lupusgalicia.org\/wp-content\/uploads\/2017\/09\/image_content_232091_20170728131329-300x164.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=2013#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"La FDA aprueba una nueva formulaci\u00f3n autoinyectable de Benlysta"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2013"}],"version-history":[{"count":2,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2013\/revisions"}],"predecessor-version":[{"id":2016,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2013\/revisions\/2016"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}